Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 20, 2017
Kiadis Pharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ATIR101™
Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow ...
September 20, 2017
DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083
VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 20, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the ...
September 20, 2017
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
CUPERTINO, Calif., Sept. 20, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) announced today that Dr. Myriam Theeuwes has joined DURECT as Senior Vice President, Clinical Development. ...
September 20, 2017
HTG Announces Issuance of Two Method Patents Related to its Technology
TUCSON, Ariz., Sept. 20, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today ...
September 20, 2017
Lipocine Announces FDA Advisory Committee Meeting for TLANDO™
SALT LAKE CITY, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced that the Bone, Reproductive and Urologic Drugs ...
September 20, 2017
Altimmune Announces its Phase 2 Flu Vaccine Trial with NasoVAX Open for Enrollment
GAITHERSBURG, Md., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced that they have been cleared by the FDA ...
September 20, 2017
AIT Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference
REHOVOT, Israel and NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (AITB), a clinical stage anti-microbial therapeutic company treating respiratory diseases with ...
September 18, 2017
Ignyta to Present at the Ladenburg Thalmann 2017 Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, ...
September 18, 2017
BioTime Awarded Grant from the NIH
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American:BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it has been ...
September 18, 2017
Kamada Announces CFO Transition
REHOVOT, Israel, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that Gil ...
September 18, 2017
HTG Molecular Diagnostics Receives ISO 13485 Certification for Health Canada CMDCAS Requirements
TUCSON, Ariz., Sept. 18, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today ...
September 18, 2017
Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors
PALO ALTO, Calif., Sept. 18, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the ...
September 18, 2017
Prothena Presents New Research Supporting Clinical Relevance of Cardiac Biomarker NT-proBNP in AL Amyloidosis
DUBLIN, Ireland, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of ...
September 18, 2017
CymaBay Therapeutics to Present at Two Investor Conferences
NEWARK, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
September 18, 2017
DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer
VANCOUVER, British Columbia, and MENLO PARK, Calif., Sept. 18, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the ...
September 18, 2017
Gemphire to Present at Cantor Fitzgerald Global Healthcare Conference on September 26 in New York
LIVONIA, Mich., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
September 18, 2017
Achaogen Adds Liz Bhatt as Chief Business Officer
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative ...
September 18, 2017
Advaxis to Present at Cantor Fitzgerald Global Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Anthony Lombardo, interim ...
September 14, 2017
Transgene: First Half-Year 2017 in Line with Our Objectives: All Clinical Programs Progressing and New Collaboration Agreements Signed
Transgene (TNG.PA), a biotechnology company focused on designing and developing viral-based immune-targeted therapies, today announced its financial results for the six-month period ended June 30, ...
September 14, 2017
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Malignant Melanoma
IRVING, Texas, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced that the United ...
Page 92 of 117